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Abstract
Background: Neonatal hearing screening (NHS) has been routinely offered as a vital component of early
childhood care in developed countries, whereas such a screening program is still at the pilot or preliminary stage
as regards its nationwide implementation in developing countries. To provide significant evidence for health policy
making in China, this study aims to determine the cost-effectiveness of NHS program implementation in case of
eight provinces of China.
Methods: A cost-effectiveness model was conducted and all neonates annually born from 2007 to 2009 in eight
provinces of China were simulated in this model. The model parameters were estimated from the established
databases in the general hospitals or maternal and child health hospitals of these eight provinces, supplemented
from the published literature. The model estimated changes in program implementation costs, disability-adjusted
life years (DALYs), average cost-effectiveness ratio (ACER), and incremental cost-effectiveness ratio (ICER) for
universal screening compared to targeted screening in eight provinces.
Results and discussion: A multivariate sensitivity analysis was performed to determine uncertainty in health effect
estimates and cost-effectiveness ratios using a probabilistic modeling technique. Targeted strategy trended to be
cost-effective in Guangxi, Jiangxi, Henan, Guangdong, Zhejiang, Hebei, Shandong, and Beijing from the level of 9%,
9%, 8%, 4%, 3%, 7%, 5%, and 2%, respectively; while universal strategy trended to be cost-effective in those
provinces from the level of 70%, 70%, 48%, 10%, 8%, 28%, 15%, 4%, respectively. This study showed although there
was a huge disparity in the implementation of the NHS program in the surveyed provinces, both universal strategy
and targeted strategy showed cost-effectiveness in those relatively developed provinces, while neither of the
screening strategy showed cost-effectiveness in those relatively developing provinces. This study also showed that
both strategies especially universal strategy achieve a good economic effect in the long term costs.
Conclusions: Universal screening might be considered as the prioritized implementation goal especially in those
relatively developed provinces of China as it provides the best health and economic effects, while targeted
screening might be temporarily more realistic than universal screening in those relatively developing provinces of
China.
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As adequate auditory stimulation in early childhood is
fundamental for optimal speech and language develop-
ment as well as for the acquisition of literacy skills, early
hearing detection and interventions for deaf children are
essential [1,2]. A failure to undertake early hearing
detection and intervention within the first year of life
for permanent congenital and early-onset hearing
impairment (PCEHI) might lead to severe and irreversi-
ble impairment in language acquisition and speech
development in early life and poor educational and
occupational performance in adulthood [3-7]. However,
compared to those major disease set out in the Millen-
nium Development Goals, PCEHI, as a non-fatal but
life-long disease, has been neglected particularly in
developing countries [8-10].
Neonatal hearing screening (NHS) program has made
a rapid development in recent years. The benefit of
NHS is that it allows most PCEHI to be detected early
enough for optimal intervention [11,12]. NHS has been
routinely offered as a vital component of early childhood
care in developed countries, whereas such a screening
program is still at the pilot or preliminary stage as
regards its nationwide implementation in developing
countries where hearing care services, such as the provi-
sion of hearing aids, only cover approximately 1% of all
the population [13].
Cost-effectiveness analysis (CEA) has been used as a
tool to prioritize scarce health resources, which allows
the comparison of various intervention options [14,15].
Although CEA is currently the cornerstone of health
investment, it might be the only one approach implemen-
ted in the developing countries in Africa and Asia to
evaluate selected interventions for hearing impairment
[16]. The prospects of any immediate action to imple-
ment NHS programs are still uncertain in most of devel-
oping countries, since the current approach to global
disease prioritization and health resource allocation
requires vital data in an environment where funds to
invest are always scarce.
In China, the largest developing country in the world,
the Ministry of Health has recently decided to address the
issue of non-fatal congenital diseases in neonatal health
care which have until now been neglected but have a con-
siderable impact on the individual, family and society.
There is now a political commitment to scale-up a hospi-
tal-based neonatal hearing screening program, which will
include expanded screening, diagnosis and intervention
services [17]. A key policy question on how to implement
the program under a system of decentralized health finan-
cing and authority at the provincial level has been raised.
Therefore, this study aims to determine cost-effectiveness
of the NHS program implementation, in case of eight
provinces of China, in order to support evidence-based
national policy making in China.
Methods
Cost-effectiveness model
In the present study, we modeled the cost-effectiveness of
two screening programs: universal screening which cov-
ers all live births, and targeted screening which targets
those with one or more risk factors (Figure 1). Universal
NHS detects infants with the disorder who have no
known risk factors associated with PCEHI, which
accounts for approximately 50% of PCEHI cases [18,19].
The targeted screening of newborns with risk factors for
hearing impairment is one alternative to universal NHS.
Although the universal strategy has been widely recom-
mended as it can detect more cases, recently Joint Com-
mittee on Infant Hearing (JCIH) suggested that targeted
screening might be more appropriate for developing
countries because of cost considerations [20].
A natural history model of all infants with and without
hearing impairments was developed to characterize the
process of screening, diagnosis and interventions through
all possible stages. All neonates annually born in eight
provinces (Beijing, Shandong, Hebei, Henan, Jiangxi,
Guangxi, Guangdong, and Zhejiang) of China from 2007
to 2009 were simulated (Figure 2). In these 8 provinces
of China, Beijing, Shandon g ,H e b e i ,G u a n g d o n g ,a n d
Zhejiang are relatively developed provinces, whereas
Henan, Jiangxi, and Guangxi are relatively developing
provinces. The model determined the proportion of
infants with PCEHI in the simulated cohort who would
potentially benefited from the NHS program, where
detection by a process of screening and diagnosis occurs
before 6 months and intervention before 12 months.
Probability parameters
Depending on the program coverage and screening strate-
gies, neonates could either receive or not receive screen-
ing. Neonates screened consisted of false-positive and
false-negative cases, and those with a positive result are
referred to the diagnosis center. With the probability of
drop-out from the diagnosis center and an inaccessibility
of interventions, referred neonates might not be either
diagnosed or receive interventions. In the final instance,
infants with the disorder would have treated or untreated
health outcomes, depending on whether they received
screening, diagnosis and interventions.
In this model, probability parameters potentially
affecting cost-effectiveness are the proportion of infants
with one or more high risks, the prevalence of PCEHI
in the general population and high-risk population, the
sensitivity, specificity, and coverage of the screening pro-
gram which shows neonates screened among those
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Page 2 of 10Figure 1 The tree model for cost-effectiveness of two screening strategies (universal screening and targeted screening).
Figure 2 The map of study sites including Beijing (☆), Shandong, Hebei, Henan, Jiangxi, Zhejiang, Guangxi and Guangdong.
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or high-risk population), diagnosis rate which shows
those diagnosed before 6 months among those referred
after the screening, and intervention rate which shows
infants fitted with hearing aids or cochlear implants and
that have started the rehabilitation course before 12
months of age among those with the disorder as
detected by the diagnosis process (Table 1). The cover-
age, diagnosis rate and intervention rate were calculated
based on data in the newly established database in the
study sites, while others were acquired from literature
review.
Costs for the program implementation
We followed the guideline developed by the World
Health Organization (WHO) [37] to estimate costs for
the program implementation. These included capital
costs (e.g. office buildings, furniture and equipment),
recurrent costs such as the salaries of the personnel,
materials and supplies, utilities, equipment maintenance,
database management, training and transport, and
patient-level costs which were composed of the registra-
tion fee, screening tests, diagnosis tests, drugs, treatment
with a hearing aid, treatment with a cochlear implant,
rehabilitation courses, and transportation charges for
diagnostic procedures and treatments. The capital invest-
ments of office buildings, furniture and equipment were
annualized by depreciation, for which the life spans were
standardized by Ministry of Finance of the People’s
Republic of China and Ministry of Health of the People’s
Republic of China [38] Table 2 summarized cost esti-
mates for cost-effectiveness analysis. Data for the cost
estimates came from the annual financial report of
screening facilities, diagnosis centers and rehabilitation
facilities in the surveyed provinces, with the cooperation
of experts in hospital accounting. Costs were first calcu-
lated in RMB, the Chinese currency, with the costs across
different years being adjusted in accordance with the
price level in 2009 based on the GDP deflator. They were
then converted into international dollars (Int$), by divid-
ing Purchasing Power Parities [39].
Apart from the costs of program implementation for
estimates of cost-effectiveness, it is reasonable to assume
(and thus estimate) that money would be saved if early
detection and intervention was given. Early detection
and intervention may bring expenditure on special edu-
cation and rehabilitation reduction, social and medical
services support decrease and incomes increase. How-
ever, there was no report on the long-term costs of the
disorder from the published literature in China. In our
model, we preliminarily attempted to estimate the
potential long-term costs saving from the use of the
NHS program, including medical services, special educa-
tion and rehabilitation. It was assumed that improved
language outcomes would result in a 10% decrease in
special education costs and a 75% decrease in vocational
rehabilitation costs [40,41]. It was estimated based on
data from hospitals, disabled people’s federations [42]
Table 1 Parameter values and plausible ranges for probability variables used in the baseline and sensitivity analysis
Items Baseline Range for sensitivity analysis References
High-risk infants 7% 6-8% [21]
Prevalence in all live-born 0.30% 0.2-0.4% [22]
[23]
[24]
[25]
[26]
Prevalence in high risk infants 3.00% 1.15-3.59% [27]
[28]
[29]
[30]
[31]
[32]
Sensitivity 95% 90-100% [17]
[32]
[33]
Specificity 95% 90-100% [18]
[34]
[35]
Coverage 60% 15-99% [36]
(Primary data)
Diagnosis rate 50% 20-95% [36]
(Primary data)
Intervention rate 50% 10-95% [36]
(Primary data)
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tion agency. Table 3 presented a summary of the long-
term costs saving.
Data collection
Data collection in the field included two components:
costs related to the screening program which were
acquired from general hospitals and maternal and child
health hospitals providing screening and diagnosis ser-
vices, and rehabilitation facilities, and transition probability
parameters including the coverage of screening program,
the diagnosis rate and intervention rate which were
calculated based on data from the database established at
the provincial level. A multiple of three parameters shows
the proportion of infants with PCEHI potentially benefit-
ing from the screening program among the targeted popu-
lation (all or high-risk infants), in this study, calculated as
the proportion of the benefit population [43].
A f t e rp e r m i s s i o nt ou s et h ed a t a b a s eb yt h ed i s t r i c t
health agencies, the data of the province were acquired.
For the costs estimate, all facilities providing screening,
diagnosis, and rehabilitation services were visited in
selected districts and the annual financial report was
analyzed by an expert in hospital accounting.
Table 2 Parameter values and plausible ranges for cost estimates per case used in the baseline and sensitivity analysis
(Int $)
Items Hearing screening method Baseline Ranges for sensitivity analysis
Minimum Maximum
Screening
Program costs
Capital costs OAE 240,813,700 170,712,610 307,291,540
OAE+AABR 429,951,870 322,027,570 559,461,040
Recurrent costs OAE 150 100 200
OAE+AABR 230 130 360
Patient costs 30 10 50
Diagnosis
Program costs
Capital costs 15,950,600 11,014,773 21,467,600
Recurrent costs 240 130 360
Patient costs 170 90 310
Intervention
Program costs
Capital costs 13,829,240 12,430,260 15,554,540
Recurrent costs 290 200 440
Patient costs 22,690 18,860 29,140
Abbreviation: Otoacoustic emission (OAE); Automated auditory brainstem response (AABR)
Table 3 Summary of estimates for long-term costs saving
Items long-term costs saving (Int $)
Untreated children with PCEHI Treated Children with PCEHI
Medical services
For cases to fit hearing aid 1,960
(1,740-2,180)
1,960
(1,740-2,180)
For cases to fit cochlear implant 40,000
(38,000-42,500)
40,000
(38,000-42,500)
Special education
(9 years compulsory education)
42,300
(40,500-45,900)
38,070
(36,450-41,310)
Rehabilitation
(Up to 15 years)
82,400
(75,200-88,400)
20,600
(18,800-22,100)
Total 166,660
(155,440-178,980)
100,630
(60,790-108,090)
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In this study, population health is expressed as the num-
ber of Disability-Adjusted Life Years (DALYs) averted as
a result of the screening program. DALYs lost due to
PCEHI were calculated as the sum of Years Lost due to
Disability (YLDs), as it is a non-fatal disorder, and the
time period is life-long. Disability weights for adult-
onset hearing impairment were adopted in the estima-
tion, 0.216 for untreated disorders and 0.168 for treated
disorders, respectively [44]. This was done because there
was no evaluation for infants and children, and lifetime
coverage rather than childhood coverage was thought to
be able to minimize the discrepancy in the long term.
Cost-effectiveness analysis
The cost-effectiveness of a given intervention is typically
expressed as costs per unit of effectiveness, with costs
measured in monetary terms and effectiveness measured
in health metrics terms. In this study, the average cost-
effectiveness ratio (ACER) is calculated for each screen-
ing strategy by determining the cost for the program’s
implementation (except long-term costs saving) and
total health effects in terms of DALYs averted. Incre-
mental cost-effectiveness ratio (ICER) shows the abso-
lute value of resources necessary to move to the next
option. We calculated ICER for different screening stra-
tegies by dividing the incremental costs by the incre-
mental health effects, in order to determine the priority
of purchasing these services at different budgetary levels.
A multivariate sensitivity analysis was performed to
determine uncertainty in health effect estimates and
cost-effectiveness ratios, using a probabilistic modeling
technique, known as Monte Carlo simulation. The simu-
lation associating the estimates of costs and health
effects as described above with each of the transition
probability parameters was performed on one parameter
at a time allowing for the input of extreme values while
keeping the other parameters fixed at the their baseline
level. The model was evaluated on 1,000 trials. It
showed that any variation in the input parameter might
result in a change of preference of strategies compared
to the baseline result.
Results
Benefit population of the current neonatal hearing
screening program
Demographic and socioeconomic information and the
indicators of the program implementation including
coverage rate, diagnosis rate and intervention rate in the
six provinces were presented in Table 4. The three vari-
ables (coverage rate, diagnosis rate and intervention
rate) determined the total number of deaf infants finally
receiving early interventions and benefiting from the
screening program. The benefit population referred to
the proportion of infants with the disorder who finally
received beneficial early hearing detection and interven-
tion. There was a huge disparity in this figure between
different provinces. In general, these figures in the
developed eastern provinces were much higher.
Cost-effectiveness of different strategies in eight
provinces
Table 5 shows implementation costs, DALYs averted,
and cost-effectiveness of different NHS strategies in
eight provinces. Based on GDP per capita in each pro-
vince and baseline of transition probability parameters,
universal strategy shows cost-effectiveness in Guang-
dong, Shandong, and Beijing, and targeted strategy
shows cost-effectiveness in Zhejiang and Hebei, while
neither of the screening strategy shows cost-effectiveness
in Guangxi, Jiangxi and Henan.
Multivariate sensitivity analyses were performed for
transition probability parameters to determine the
robustness of the model. The results suggested the vari-
ables whose range of uncertainty had a great impact on
the cost-effectiveness of the screening strategies were
the program coverage, diagnosis rate, and intervention
rate. Figure 3 showed that the increasing proportion of
the benefit population, which was estimated by multiply-
ing the three variables, reduced ACER of different stra-
tegies and gradually helped both reach better cost-
effectiveness. Targeted strategy trended to be cost-effec-
tive in Guangxi, Jiangxi, Henan, Guangdong, Zhejiang,
Hebei, Shandong, and Beijing from the level of 9%, 9%,
8%, 4%, 3%, 7%, 5%, and 2%, respectively; while universal
strategy trended to be cost-effective in those provinces
from the level of 70%, 70%, 48%, 10%, 8%, 28%, 15%,
4%, respectively.
Economic effects on long-term costs saving
Costs would be saved if early detection and intervention
was given. In our model, universal strategy and targeted
strategy led to 214,024,820 and 104,872,740 Int$ of
long-term costs saving in total which are approximately
equivalent to 0.14% and 0.07% of the annual health
expenditure [36].
At the baseline, both strategies achieve cost savings
which were greater than implementation costs. When
the proportion of benefit population expanded, the
effect of these screening strategies on the long-term
costs saving become more and more significant, espe-
cially those of universal strategies, exceeding the total
costs of the screening program implementation, suggest-
ing a good economic effect in the long term (Figure 4).
Discussion
WHO has recommended the implementation of NHS
program in member states, particularly in developing
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leading experts from variousw o r l dr e g i o n sa n da c r o s s
relevant disciplines [45]. This study found there was a
huge disparity in the implementation of the NHS pro-
gram in the surveyed provinces. In general, those devel-
oped provinces had much higher program coverage,
diagnosis rates and intervention rates, leading to a larger
benefit population and helping the NHS program
achieve better cost-effectiveness. In fact, the NHS pro-
gram had been adopted several years in some developed
provinces in China with financial and administrative
supports by local health government [46]. Under the
decentralization of health financing, the developed pro-
vinces have a stronger financial capacity to invest in
health programs [47]. This difference in implementation
and in underlying financial factors has also been
reflected in the national plan. Regarding the accessibility
of the screening, diagnosis and intervention services, the
short-term goal is to achieve a coverage rate of 80% in
the eastern provinces (the most developed region of
China), 40% in the moderate provinces, and 30% in the
western provinces (the least developed region of China)
by 2012, and to increase these figures to 90%, 60% and
50%, respectively, by 2015 [17].
Can the national plan help the NHS program achieve
its goal with good cost-effectiveness, health and long-
term economic effects, at both the national and the
regional level? The goal of the NHS program in China
Table 4 Basic information of study sites
Provinces Beijing Shandong Hebei Zhejiang Guangdong Henan Jiangxi Guangxi
Population
a 16,330,000 93,670,000 69,430,000 50,600,000 94,490,000 93,600,000 4,368,000 47,680,000
Birth rate (per 1,000)
a 8.32 11.11 13.33 11.26 11.96 11.26 13.86 14.19
No. of live births per year
a 135,866 1,040,674 925,502 1,053,936 1,130,100 1,053,936 605,405 676,579
GDP per capita (Int$)
b 16,644.25 7,951.80 5,684.11 10,698.20 9,479.99 4,578.86 3,612.58 3,590.28
Life expectancy
a 76.1 73.92 72.54 74.7 73.27 71.54 68.95 71.29
Development status
c Developed Developed Developed Developed Developed Moderately
developed
Moderately
developed
Less
developed
No. of screening facilities
a 548 1,402 1,296 722 1,154 1,341 602 553
No. of diagnosis centers
a 6 1 71 11 12 1 1 7 1 1 1 4
No. of rehabilitation
facilities
a
12 14 8 8 15 10 6 5
Coverage rate
d 97.8% 83.3% 91.3% 83.3% 97.0% 24.5% 30.5% 50.2%
Diagnosis rate
d 97.4% 68.3% 60.0% 60.0% 75.0% 30.2% 48.2% 21.4%
Intervention rate
d 77.1% 72.5% 76.1% 70.0% 75.0% 23.8% 33.3% 23.9%
Proportion of benefit
population
73.4% 41.3% 41.7% 35.0% 54.6% 1.8% 4.9% 2.6%
Data source:
a: Ministry of Health of the People’s Republic of China [17].
b: International Monetary Fund [39].
c: Ministry of Health of the People’s Republic of China [35].
d: Provincial data
Table 5 Implementation costs, health effects and cost-effectiveness of different NHS strategies in eight provinces
Items Guangxi Jiangxi Henan Guangdong Zhejiang Hebei Shandong Beijing
Total costs (Int $)
Universal strategy 10,498,335 23,063,105 9,121,907 39,077,961 17,144,588 33,472,076 32,326,020 4,014,771
Targeted strategy 1,416,185 2,272,838 2,403,868 6,774,350 2,022,018 4,554,258 4,880,764 1,094,184
DALY averted
Universal strategy 35 206 78 3,508 278 1,499 1,533 292
Targeted strategy 17 101 38 1,719 136 735 751 143
ACER
Universal strategy 299,952 111,957 116,948 11,140 61,671 22,330 21,087 13,749
Targeted strategy 83,305 22,503 63,260 3,941 14,868 6,196 6,499 7,652
Reference (3 times GDP per capita) 10,771 10,838 13,737 28,440 32,095 17,052 23,855 49,933
ICER
Universal strategy 504,564 198,003 167,951 18,057 106,497 37,851 35,096 19,601
Targeted strategy 83,305 22,503 63,260 3,941 14,868 6,196 6,499 7,652
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gram and to continuously expand diagnosis and inter-
vention services [17]. The rationale for implementing a
universal strategy is that it can detect more deaf infants,
providing a greater opportunity for them to experience
normal language development, while also providing
overall benefits in terms of the reduction in disability
and the improvement in health and well-being of the
Chinese population. As the program’s implementation
varies by different socioeconomic development status, a
sufficiently high coverage rate, diagnosis rate and inter-
vention rate ensure that the universal strategy achieves
good cost-effectiveness and the relevant health and eco-
nomic effects in Beijing, Shandong and Hebei; but in
the other three provinces Henan, Jiangxi and Guangxi,
where these three indicators were low, targeted strate-
gies tend to be more feasible, similar to previous policy
suggestions that have been advanced in relation to
developing countries [20,48]. Meanwhile, a pilot survey
on context-specific risk factors for PCEHI in diverse set-
tings should be implemented to facilitate the targeted
strategy.
The study also attempted to estimate the long-term
economic effect of the NHS program in China. As the
available data and evidence is limited and this is a very
preliminary approach, only costs saving in rehabilitation
and special education up to 15 years of age (at which
children finish their compulsory education) were
counted, potentially leading to an underestimate of the
economic effect. Even so, the results showed that at the
baseline, the costs saved already exceeded the imple-
mentation costs in the targeted strategies; as the propor-
tion of the benefit population expends, the economic
effect would be more and more significant, especially in
relation to universal strategies. Such results strongly
support the implementation of the NHS program and
suggest potentially greater benefits of adopting universal
strategies in China.
Our study was restricted by the limited availability of
data and evidence. First, globally, there was no strong
evidence based on randomized controlled trials for the
effectiveness of NHS on deaf infants’ language develop-
ment, and consequently, no evidence as regards the eva-
luation of their psychological and educational-related
outcomes. The impact of early intervention on long-
term cost saving remains unknown. Moreover, in China,
there has been no previous nationwide population-based
s t u d yt os u r v e yt h ee p i d e m iological status of PCEHI.
Data on the prevalence used in this study were therefore
derived from a crude estimation based on the number of
the hearing disabled population and a few regional sur-
veys. All that needs to be researched in future. Last, due
to the unavailability of child-onset disability weights for
hearing loss, we attempted to use adult-onset disability
weights instead into the economic evaluation. It may
underestimate the health effects of NHS as early detec-
tion and intervention leads to much more benefits on
children’s language development.
Conclusions
In conclusion, universal strategy can be considered as
the ultimate implementation goal as it provides the best
health and economic effects. A universal strategy is fea-
sible in provinces where screening, diagnosis and inter-
vention services are good enough to benefit sufficient
proportion of the deaf children. In the other regions, a
targeted strategy is temporarily more realistic than a
universal strategy; however, related services still need to
be scaled up to cover the targeted population as much
as possible. The reference data from this study thus are
expected to be of particular benefit in terms of the ‘roll-
ing out’ of the national plan.
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